Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?
Authors:
- 30 January 2023
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (5) , 1417-1420
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Fixed airflow obstruction relates to eosinophil activation in asthmaticsClinical & Experimental Allergy, 2018
- Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational studyAnnals of Allergy, Asthma & Immunology, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Small airway dysfunction is associated with poorer asthma controlEuropean Respiratory Journal, 2014
- Unlocking the quiet zone: the small airway asthma phenotypeThe Lancet Respiratory Medicine, 2014
- Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: A systematic reviewJournal of Allergy and Clinical Immunology, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Objective evidence of omalizumab treatment assessed by Forced Oscillation (FO)Journal of Allergy and Clinical Immunology, 2007
- Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Quantitative Structural Analysis of Peripheral Airways and Arteries in Sudden Fatal AsthmaAmerican Review of Respiratory Disease, 1991